TC
RIGL icon

TFS Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

TFS Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,142
Closed -$86K – 292
2017
Q2 		$86K Sell
3,142
-714
-19% -$19.5K 0.03% 563
2017
Q1 		$128K Sell
3,856
-5,631
-59% -$143K 0.04% 560
2016
Q4 		$226K Buy
+9,487
New +$272K 0.06% 482
2016
Q3 		– Sell
-23,176
Closed -$517K – 940
2016
Q2 		$517K Sell
23,176
-63,344
-73% -$1.57M 0.1% 364
2016
Q1 		$1.8M Sell
86,520
-38,609
-31% -$952K 0.26% 94
2015
Q4 		$3.79M Sell
125,129
-27,819
-18% -$843K 0.41% 49
2015
Q3 		$3.78M Sell
152,948
-21,792
-12% -$650K 0.36% 56
2015
Q2 		$5.61M Buy
174,740
+141,825
+431% +$5.42M 0.55% 16
2015
Q1 		$1.18M Buy
32,915
+12,398
+60% +$340K 0.12% 292
2014
Q4 		$466K Sell
20,517
-76,343
-79% -$1.54M 0.04% 599
2014
Q3 		$1.88M Buy
96,860
+22,911
+31% +$647K 0.16% 191
2014
Q2 		$2.68M Buy
73,949
+37,393
+102% +$1.27M 0.21% 126
2014
Q1 		$1.42M Sell
36,556
-11,700
-24% -$417K 0.09% 332
2013
Q4 		$1.38M Sell
48,256
-9,893
-17% -$290K 0.06% 446
2013
Q3 		$2.08M Buy
58,149
+10,775
+23% +$393K 0.09% 304
2013
Q2 		$1.58M Buy
+47,374
New +$2.15M 0.07% 430

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TFS Capital's RIGL Position: Q3 2017 in Review

TFS Capital sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 3,142 shares — an estimated $86K sold.

TFS Capital first reported a position in RIGL in Q2 2013 and held it in 16 quarters. The position peaked at $5.61M in Q2 2015. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • TFS Capital reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 3,142 Rigel Pharmaceuticals shares in Q3 2017, an estimated $86K.
  • TFS Capital first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • TFS Capital's Rigel Pharmaceuticals position peaked at $5.61M in Q2 2015.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.